ClinicalTrials.gg
CompletedNCT07869810Updated Oct 13, 2026

Emotion-Belief Intervention for Subthreshold Depression in College Students

An interventional study of Single-session emotion-belief intervention and Continuous emotion-belief intervention in Subthreshold Depression, sponsored by Huazhong University of Science and Technology. Completed at 1 site in China. Open to participants aged 17 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Huazhong University of Science and Technology · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 8 months after the study started (first participant enrolled Jan 2025, registered Sep 2026).
Updated Oct 13, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
17 Years to 30 Years
Sex
All
01

Study summary

This study was a randomized controlled trial examining the long-term efficacy of an emotion-belief intervention on depressive symptoms in college students with subthreshold depression. Participants with subthreshold depression were randomly assigned to a single-session emotion-belief intervention, a continuous emotion-belief intervention, or a sport-belief control group. Depressive symptoms, emotion beliefs, and emotion regulation were assessed at baseline and at 2, 4, and 6 months after intervention. This study was retrospectively registered.

02

Conditions studied

  • Subthreshold Depression
03

In context

Lead sponsor

Huazhong University of Science and Technology is the lead sponsor of 246 studies on the registry; 62 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 17-30 years

College students

PHQ-9 ≥ 5 and BDI-II ≥ 14 at baseline

Confirmed subthreshold depression by MINI interview

Written informed consent

Exclusion criteria

Exclusion Criteria:

  • PHQ-9 item 9 ≥ 2 (suicide risk)

Psychotic disorder

Current psychological treatment for depression or anxiety

Current psychotropic medication

History of substance use disorders

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Single-session emotion-belief intervention

    Participants received a single 20-minute computerized emotion-belief intervention.

    Behavioral: Single-session emotion-belief intervention

  • Experimental
    Continuous emotion-belief intervention

    Participants received the single-session emotion-belief intervention plus a two-week daily consolidation exercise.

    Behavioral: Continuous emotion-belief intervention

  • Active comparator
    Sport-belief control

    Participants received a structurally identical single-session intervention focused on the malleability of athletic ability.

    Behavioral: Sport-belief control

Interventions

  • BehavioralSingle-session emotion-belief intervention

    A 20-minute computerized intervention consisting of three modules: psychoeducation on neuroplasticity, reading and internalizing role-model stories, and a guided self-persuasion exercise.

  • BehavioralContinuous emotion-belief intervention

    The single-session emotion-belief intervention plus a two-week daily consolidation exercise requiring at least 10 daily records.

  • BehavioralSport-belief control

    A structurally identical single-session intervention focused on the malleability of athletic ability, serving as an active control.

06

What researchers measure

Primary outcomes

  1. Depressive symptoms (PHQ-9)

    Patient Health Questionnaire-9 (PHQ-9) total score, ranging from 0 to 27, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline, 2 months, 4 months, and 6 months after intervention

Secondary outcomes

  1. Depressive symptoms (BDI-II)

    Beck Depression Inventory-II (BDI-II) total score, ranging from 0 to 63, with higher scores indicating more severe depressive symptoms.

    Time frame: Baseline, 2 months, 4 months, and 6 months after intervention

  2. Emotion beliefs (ITES-V)

    Implicit Theories of Emotion Scale-Variant version (ITES-V) score, ranging from 1 to 5, with higher scores indicating stronger incremental beliefs about emotion.

    Time frame: Baseline, 2 months, 4 months, and 6 months after intervention

07

Study locations

1 site
  • School of Education, Huazhong University of Science and Technology
    Wuhan, Hubei 430074, China
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data will be made available from the corresponding author upon reasonable request.

Time frame: Available from the corresponding author upon reasonable request. No fixed end date.

Access criteria: Available from the corresponding author upon reasonable request.

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07869810
Responsible party
Meiqi Li (Principal Investigator, Huazhong University of Science and Technology) — Principal investigator
First posted
Oct 13, 2026
Start date
Jan 1, 2025
Primary completion
Sep 10, 2025
Completion
Sep 10, 2025
Last update
Oct 13, 2026

Study contacts

Jianwen Chen, PhD
study director · Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion